anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Plants possess a robust and sophisticated innate immune system against pathogens and must balance growth with rapid pathogen detection and defense. The intracellular receptors with nucleotide-binding leucine-rich repeat (NLR) motifs recognize pathogen-derived effector proteins and thereby trigger the immune response. The expression of genes encoding NLR receptors is precisely controlled in multifaceted ways. The alternative splicing (AS) of introns in response to infection is recurrently observed but poorly understood. Here we report that the potato (Solanum tuberosum) NLR gene RB undergoes AS of its intron, resulting in 2 transcriptional isoforms, which coordinately regulate plant immunity and growth homeostasis. During normal growth, RB predominantly exists as an intron-retained isoform RB_IR, encoding a truncated protein containing only the N-terminus of the NLR. Upon late blight infection, the pathogen induces intron splicing of RB, increasing the abundance of RB_CDS, which encodes a full-length and active R protein. By deploying the RB splicing isoforms fused with a luciferase reporter system, we identified IPI-O1 (also known as Avrblb1), the RB cognate effector, as a facilitator of RB AS. IPI-O1 directly interacts with potato splicing factor StCWC15, resulting in altered localization of StCWC15 from the nucleoplasm to the nucleolus and nuclear speckles. Mutations in IPI-O1 that eliminate StCWC15 binding also disrupt StCWC15 re-localization and RB intron splicing. Thus, our study reveals that StCWC15 serves as a surveillance facilitator that senses the pathogen-secreted effector and regulates the trade-off between RB-mediated plant immunity and growth, expanding our understanding of molecular plant-microbe interactions.
AIMS: Early evaluation of the natriuretic response is recommended to guide diuretic therapy in acute decompensated heart failure (ADHF). However, its implementation in daily practice is hampered by implementation barriers and increased time constraints. The Readily Available Urinary Sodium Analysis in Patients with Acute Decompensated Heart Failure (EASY-HF) study assessed the feasibility, efficacy and safety of a nurse-led urinary sodium-based diuretic titration protocol with the use of a point-of-care urinary sodium sensor.
METHODS AND RESULTS: The EASY-HF study was a single-centre, randomized, open-label study comparing diuretic management at the treating physician's discretion as standard of care (SOC) with a nurse-led natriuresis-guided protocol in patients with ADHF. The LAQUAtwin Sodium Meter (HORIBA) was used as point-of-care sensor to measure urine sodium concentration. The primary endpoint was natriuresis after 48 h. Secondary endpoints included safety profile and user-friendliness of both the protocol and the point-of-care sensor. Sixty patients were randomized towards SOC (n = 30) versus protocolized care (n = 30). The mean age was 80 ± 8 years, 25% were women and median N-terminal pro-B-type natriuretic peptide was 4667 (2667-7709) ng/L. Natriuresis after 48 h was significantly higher in the protocolized versus SOC group (820 ± 279 vs. 657 ± 273 mmol; p = 0.027). Pre-defined safety endpoints were similar among both groups. The sensor-based protocol was evaluated as easy to use by the nursing staff, and preferred over urinary collections.
CONCLUSION: A nurse-led diuretic titration protocol via a point-of-care urinary sodium sensor was feasible, safe and resulted in an increased natriuresis in ADHF compared to SOC.
Impressions of objects for dental or other purposes are taken by producing a pasty mixture comprising a polymerizable vinyl compound, a solvent capable of forming a gel with the vinyl compound in its polymerized state, and a filler and/or a substance which increases the viscosity of the solvent, adding a polymerization catalyst so as to initiate polymerization of the vinyl compound and contacting the pasty mixture with the object before gelformation while in contact with the object.  The vinyl compound may be methacrylic or acrylic acid or mixtures thereof with fumaric and maleic acids; instead of the acids, their salts, amides or hydroxyalkyl esters may be used. Preferably a monofunctional vinyl compound is used in admixture with a polyfunctional vinyl compound which may be a polyamide of acrylic or methacrylic acid and an organic compound containing at least two amino groups such as ethylene diamine or hexamethylene diamine, or may be triacrylformal.  The catalyst may be potassium persulphate or a redox system may be used; polymerization may take place under the influence of ultra-violet light.  The solvent may be water or glycerine or a mixture thereof.  Suitable fillers are calcium sulphate and carbonate, titanium dioxide, aluminium oxide, magnesia, magnesium carbonate, zinc oxide, filaments of linear polyamides, bentonite and talc, and substances which increase the viscosity of the solution may be silica gels, agar-agar, gelatine, dextrine, methyl cellulose, sugar, alginates and polyacrylates.
The dialkylaminoethyl esters of 4-amino-2-hydroxy-benzoic acid in which each alkyl group contains not more than 10 C atoms, are prepared by reacting 4-nitrosalicylic acid in an organic solvent such as methylene chloride, benzene or carbon tetrachloride with thionyl chloride to produce nitrosalicylic acid chloride, which is reacted with the desired aminoethanol to produce the dialkyl aminoethyl ester of 4-nitro-salicylic acid.  This is then reduced with hydrogen in the presence of a hydrogenation catalyst such as the noble metals.  The esters produced are anaesthetics (see Group VI).ALSO:An anaesthetic composition comprises a mixture of a dialkyaminoethyl ester of 4 - amino - 2 - hydroxy - benzoic acid (A) and a dialkylaminoethyl ester of a N - monosubstituted 4 - amino - 2 - hydroxy - benzoic acid (B), each of the alkyl groups in both esters containing not more than 10 carbon atoms.  The mixture consists of 80 - 99 per cent A and 1 to 20 per cent B.  It is preferred that the N - alkyl substituent of B contains not more than 4 carbon atoms, e.g. n - butyl.  Specified are the dimethylaminoethyl and the diethylaminoethyl esters of 4 - amino - 2 - hydroxy - benzoic acid and 4 - n - butylamino - 2 - hydroxy benzoic acid.  Pharmaceutical and veterinary preparations, are obtained by dissolving the anaesthetic mixture in a solvent suitable for injection into the human or animal body, e.g. water or physiological sodium chloride solution.  Vasoconstrictors such as adrenaline, noradrenaline and l - o - dihydroxy - phenylpropanolamine hydrochloride may be added.  The dialkylaminoethyl esters of the N - substituted 4 - amino - 2 - hydroxybenzoic acid are produced according to Specifications 736,960 and 760,003 [both in Group IV(b)].  Substance A is produced by reacting 4-nitro salicylic acid with thionyl chloride (see Group IV(b)).
Healthy control subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will undergo an NMR test to characterize brain metabolism under hypoglycemia.
PURPOSE: A pharmaceutical composition containing a Smilax china Linne extract is provided to reduce body fat and fat and visceral fat and to prevent or treat obesity. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains a Smilax china Linne extract as an active ingredient. The Smilax china Linne extract is prepared from Smilax china Linne stems or leaves. The composition reduces liver fat or visceral fat. The fat includes neutral lipid, cholesterol, or free fatty acid. The visceral fat includes epididymal fat, or mesenteric fat. The composition reduces the expression of LXRalpha(liver X receptor alpha), SREBP1-C(sterol response element binding protein), CD36(fatty acid translocase) or aP2(fatty acid binding protein). A food composition for treating or relieving obesity contains the extract as an active ingredient.
Participants will receive clinical care following Moffitt standards for the patients disease type and therapeutic setting. Adjuvant participants will receive one year \[currently 9-18 cycles\] of therapy with avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab, relatlimab, or currently approved standard of care treatment, either alone or in combination. Blood samples will be collected at 1) baseline (upon arrival to clinic) and 2) post-infusion. Blood samples will be obtained on the first, third, midpoint, and final infusion dates.
Chronic exposure to intense noise causes temporary or permanent hearing loss. The effects of exposure to intense noise on the auditory system are well explained, but the number of studies that observes the effects of noise on the vestibular system is limited. It has been stated that intense noise may affect the peripheral vestibular system and consequently cause problems in balance mechanisms. The aim of this study was to investigate the effects of exposure to chronic noise on vestibular functions and balance in Edirne Band musicians.

Twenty-two individuals working in the Edirne Band for at least 5 years and over 18 years of age who did not have a diagnosed vestibular disorder, no cervical vertebrae problem, no musculoskeletal system problems during the evaluation and a control group of 22 individuals working at Trakya University and with similar sociodemographic characteristics to the experimental group were included in the study. The socio-demographic questionnaire was used to inquire about the demographic characteristics of individuals and alcohol-cigarette use, the Activity-Specific Balance Confidence Scale to assess how they felt about the balance, and the Dizziness Handicap Inventory to determine the quality of life-related to dizziness. A 3D ultrasonic system was used to assess the static and dynamic balance of the individuals.
The emergence of inflammatory diseases is a heavy burden on modern societies. Cannabis has been used for several millennia to treat inflammatory disorders such as rheumatism or gout. Since the characterization of cannabinoid receptors, CB1 and CB2, the potential of cannabinoid pharmacotherapy in inflammatory conditions has received great interest. Several studies have identified the importance of these receptors in immune cell migration and in the production of inflammatory mediators. As the presence of the CB2 receptor was documented to be more predominant in immune cells, several pharmacological agonists and antagonists have been designed to treat inflammation. To better define the potential of the CB2 receptor, three online databases, PubMed, Google Scholar and clinicaltrial.gov, were searched without language restriction. The full texts of articles presenting data on the endocannabinoid system, the CB2 receptor and its role in modulating inflammation in vitro, in animal models and in the context of clinical trials were reviewed. Finally, we discuss the clinical potential of the latest cannabinoid-based therapies in inflammatory diseases.
Participants will be given 6 FMT capsules twice a week for 24 weeks. The FMT capsules derived from healthy donors.
PURPOSE:To provide a new alisol having a specific molecular structure, activating the activity of choline acetyltransferase, and useful for cerebral function-improving agents used for the therapy of Alzhemmer's disease, etc., severe amyosthenma-treating medicines, gastrointestinal function improving agents, etc. CONSTITUTION:A new alisol of formula I. A cerebral function-improving agent contains an alisol compound of formula II (R1 to R4 are H, OH, acetyl ; R1 and R3 together form 0) as an active ingredient. The cerebral function-improving agent is compounded with an excipient, a binder, a disintegrator, a surfactant, a lubricant, a flowability- accelerating agent, a flavor, a coloring agent, a perfume, etc., and subsequently prepared into the form of an oral agent such as tablets, capsules, granules, pills or powder, an injection, a suppository, etc. The prepared medicine activates the activity of choline acetyltransferase and is used as a medicine such as a cerebral function-improving agent for treating Alzheimer's disease and Alzheimer type dementia, a therapeutic medicine for severe amyosthenia, a gastrointestin function-improving agent, etc. These compounds are obtained extracting a galenical: Alismatis Rhizoma and, if necessary, subsequently chemically modifying the extract.
Previous studies have shown that low doses of ketamine, an N-methyl-D-aspartate receptor antagonist, produce aberrantly strong internal representations of associatively activated but absent stimuli in humans and nonhuman animals, suggesting the validity of ketamine treatment as a preclinical model of the positive symptoms of schizophrenia, including hallucinations and delusions. However, whether acute ketamine treatment also impairs the ability to ignore present but informationally redundant stimuli, which is another hallmark of schizophrenia, remains unclear. Accordingly, the present study investigated whether injections of low-dose ketamine attenuate Kamin blocking in an appetitive conditioning preparation in mice. Mice in the blocking group were initially trained with A+ conditioning (i.e., conditioned stimulus A paired with a sucrose solution), followed by compound AX+ training, before the conditioned responses to the cue X were tested in extinction. The animals in the control group received B+ training before the AX+ training. Half of the mice in each group received an injection of 16 mg/kg ketamine before each compound conditioning session and the extinction test, whereas the other half received saline. The results showed a reliable blocking effect in the saline-treated mice, whereas the blocking effect was absent in the ketamine-treated mice. Specifically, the absence of blocking was due to the ketamine-treated mice learning about the blocked cues. This finding further validates the use of low-dose ketamine as a preclinical model of schizophrenia. It also suggests a possible link between hallucination-like aberrant processing of absent events and a reduced ability to suppress attentional processing of task-irrelevant stimuli. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
A patient support apparatus for supporting a patient wirelessly communicates with one or more tags using one or more RF transceivers. A controller onboard the patient support apparatus determines a position of the tag. The controller also receives an identifier from the tag and uses it to determine if the tag is attached to a patient or a device. If attached to a patient, the controller may allow a caregiver to activate a patient movement monitoring function. The movement monitoring function may monitor whether the patient exits the patient support apparatus, whether the patient has been turned, whether the patient is at risk of developing bed sores, and/or other aspects. If the tag is attached to a device, the controller automatically determines whether to associate the device with the patient support apparatus. The controller may also determine the location of the patient support apparatus from the RF transceivers.
The invention relates to an externally applied medicament for treating porcine foot-and-mouth disease and PRRS, which is processed and confected by the bulk drugs with parts by weight as follows: 2-3 parts of dried rhizome of rehmannia, 2-3 parts of Flos Daturae, 1-2 parts of borneol and 0.5-1 part of snake skin. The optimal matching proposal of the invention is as below: 2 parts of dried rhizome of rehmannia, 2 parts of Flos Daturae, 1 part of borneol and 0.5 part of snake skin. The confecting method comprises the steps of weighing the bulk drugs according to the above parts by weight, grinding the bulk drugs, soaking the ground bulk drugs in liquor with alcoholicity above 56 degrees for 30-40 days, filtering the liquor and removing residues to prepare medicinal liquor. The medicinal liquor is sprayed or rubbed for 5-6 times every day and 7-day is a course of treatment. The drugs of the invention are reasonable in compatibility, address both the symptoms and root causes, are relevant to pathogenesis and have special effects, thus obtaining satisfactory treatment effects. The medicament features abundant drug sources, simple preparation method, low price, convenient use and no toxic side effects.
Many different non-pharmacological methods are used to cope with adverse conditions such as pain caused by invasive procedures in children. One of these non-pharmacological methods is distraction. The American Pain Association recommends the use of distractions for pain control in children. By focusing the child's attention in another direction, the child's pain is controlled and reduced. As distraction methods, video games, virtual reality glasses, listening to music, watching cartoons, blowing balloons, reading books, blowing windmill toys, parent-provide distraction are used.

The aim of this study is to determine the effects of parent-provide distraction and windmill toy blowing in reducing pain during blood collection in children aged 6-12 years. Power analysis was performed to determine the number of people to be included in the research. The strength of the test was calculated using the G\*Power 3.1 program. As a similar research in the relevant literature, the effect size of the difference in pain was calculated as 1.557 in the research conducted by Orhan (2020). In order to exceed the 95% value in determining the strength of the study, 51 people, including 17 people in groups with a significance level of 5% and an effect size of 1,557, must be reached (df=32; t=2,036). In the research, it was aimed to reach a total of 66 people, including 22 people in groups, taking into account the high strength of the test and the losses.

The Information Form, Wong Baker Faces Scale, VAS will be used for data collection. First of all, those who meet the criteria for inclusion in the research and research the purpose of the research will explain to the parents who volunteered to participate and their children by explaining the purpose of the research information about the research will be provided by the executor. Then about their participation in the study written and oral consent will be obtained from parents, and oral consent will be obtained from children. By obtaining information from the parent the information form will be filled out by the researcher before the blood collection procedure. Blood collection procedure it will be performed by a single experienced nurse Parental participation in the group of diverting attention information about the riddles will be provided by the researcher. By the research manager parents and children will be given information about the Wong Baker Faces Scale. Research manager children in the windmill toy blowing group will be supervised by blowing the windmill. No intervention will perform to reduce pain in the control group. In all groups, as soon as the procedure is completed and 1 minute after the procedure, the child's pain will be evaluated with the Wong Baker Faces Scale. The nurse and the parent will evaluate the child's pain with VAS. During the evaluation, pain assessments will be made in such a way that the child, parent and nurse will not see each other in order not to be affected by each other. It is estimated that the data collection process will take about 10-15 minutes.
The invention discloses a pharmaceutical composition for treating brain gliomas and application of the pharmaceutical composition. The pharmaceutical composition is prepared from filtrate obtained by subjecting traditional Chinese medicinal materials to heat reflux extraction by an ethanol solution. The pharmaceutical composition comprises, by weight, 15-25 parts of sargassum pallidum (Turn.) C.Ag., 30-37 parts of vernonia patula (Ait.) Merr., 30-37 parts of cynodon dactylon (L.) Pers., 10-18 parts of airpotato yam rhizome, 9-15 parts of fiveleaf akebia fruit, 9-15 parts of flowers of fragrant plantainlily, 11-20 parts of common burreed rhizome, 9-15 parts of concretio silicea bambusae and 9-15 parts of gastrodia tuber. The pharmaceutical composition gives play to efficacy by inducing glioma cell apoptosis by multiple target points, thereby having good brain glioma treatment activity.
The objective of the study is to test a strategy for optimizing Set and Setting for psilocybin-assisted therapy of alcohol use disorder. Psilocybin shows promise in early trials for alcohol use disorder, but initial results suggest that patients with alcohol use disorder may be less likely to achieve a mystical experience with standard doses of psilocybin. Optimizing Set and Setting for the psilocybin experience may improve outcomes without requiring higher drug doses. The current study will complete a pilot randomized clinical trial to assess the feasibility, safety, and tolerability of Visual Healing Set and Setting (N=10) versus standard Set and Setting procedures (N=10) in participants with alcohol use disorder undergoing open-label psilocybin 25 mg therapy. In the Visual Healing condition, participants will view nature-themed video programs during the Prep session and during the Ascent phase of the psilocybin experience. Anecdotal reports and reviews suggest that viewing Visual Healing creates a tranquil and calming environment that fosters a stronger connection between the viewer and nature. Psilocybin increases the users feeling of connection to nature and having an intention to connect with nature during the psychedelic session is associated with better outcomes of psychedelic-assisted therapy in initial studies. Reducing pre-dosing anxiety/apprehension and enhancing connections to nature with Visual Healing may improve outcomes of psychedelic-assisted therapy without the need for higher psilocybin doses.
RATIONALE: Pyogenic spondylodiscitis is an infectious spinal disease that causes significant motor dysfunctions. Its diagnosis can be challenging owing to its rapid onset and nonspecific symptoms.
PATIENT CONCERNS: A 79-year-old Japanese man with a history of type 2 diabetes mellitus and polymyalgia rheumatica presented to our department with tongue pain. Following partial glossectomy and wisdom tooth extraction under general anesthesia, on 10 postoperative day (POD) the patient developed right-sided abdominal pain and difficulty in walking. On 12 POD, the patient was admitted to a municipal hospital due to respiratory distress and paraplegia.
DIAGNOSES: The patient was diagnosed with pyogenic spondylodiscitis and empyema. Blood tests revealed elevated C-reactive protein levels (36.5), white blood cell count (19,570), and neutrophil count (17,867).
INTERVENTIONS: The patient received meropenem hydrate 3 g/2 days as empiric antibiotic treatment for acute infection. Upon admission to the emergency department on 16 POD, the lung abscess was drained, hemilaminectomy was performed.
OUTCOMES: Blood cultures, sputum tests, and cultures from the thoracic and spinal abscesses drained during surgery revealed methicillin-sensitive Staphylococcus aureus. The infection was successfully managed, and the respiratory disturbance and inflammatory response improved. However, the lower half of the patient body remained paralyzed. Subsequently, the patient was transferred to a rehabilitation facility on 45 POD. The patient continued to undergo functional restoration training, gradually regained function, and eventually achieved the ability to walk with grasping gait.
LESSONS: This is the first case report of S aureus causing pyogenic spondylodiscitis and empyema due to blood stream infection from a post-oral surgical wound. Pyogenic spondylodiscitis arising from a secondary hematogenous infection is difficult to diagnose and can lead to severe functional impairment. Prompt and appropriate diagnosis and treatment based on detailed patient interviews, additional blood tests, and computed tomography are essential.